

Journal of Visualized Experiments

Characterization at the molecular level using robust biochemical approaches of a new kinase protein --Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE59820R2
Full Title:	Characterization at the molecular level using robust biochemical approaches of a new kinase protein
Keywords:	Cell line culture, transient transfection, immunoprecipitation, Western blot, kinase activity, gamma[32P] ATP labeling, phospho-specific antibody
Corresponding Author:	Béatrice Vallée CNRS Campus Orleans Orleans, FRANCE
Corresponding Author's Institution:	CNRS Campus Orleans
Corresponding Author E-Mail:	beatrice.vallee@cnr.fr
Order of Authors:	Béatrice Vallée Michel Doudeau Fabienne Godin Helene Benedetti
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Orleans, France

TITLE:

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein

AUTHORS & AFFILIATIONS:

Béatrice Vallée, Michel Doudeau, Fabienne Godin, and Hélène Bénédetti

Centre de Biophysique Moléculaire, CNRS, UPR 4301, University of Orléans and INSERM, 45071 Orléans Cedex 2, France

Corresponding Author

Béatrice Vallée

Email Address : beatrice.vallee@cnrs-orleans.fr

Email addresses of Co-authors

Michel Doudeau (michel.doudeau@cnrs-orleans.fr)

Fabienne Godin (fabienne.godin@cnrs-orleans.fr)

Hélène Bénédetti (helene.benedetti@cnrs-orleans.fr)

KEYWORDS:

Cell line culture, transient transfection, immunoprecipitation, Western Blot, kinase activity, γ [^{32}P] ATP labeling, phospho-specific antibody.

SUMMARY:

We characterized a new kinase protein using robust biochemical approaches: Western Blot analysis with a dedicated specific antibody on different cell lines and tissues, interactions by coimmunoprecipitation experiments, kinase activity detected by Western Blot using a phospho-specific antibody and by γ [^{32}P] ATP labeling.

ABSTRACT:

Extensive whole genome sequencing has identified many Open Reading Frames (ORFs) providing many potential proteins. These proteins may have important roles for the cell and may unravel new cellular processes. Among proteins, kinases are major actors as they belong to cell signaling pathways and have the ability to switch on or off many processes crucial to the fate of the cell, such as cell growth, division, differentiation, motility, and death.

In this study, we focused on a new potential kinase protein, LIMK2-1. We demonstrated its existence by Western Blot using a specific antibody. We evaluated its interaction with an upstream regulating protein using coimmunoprecipitation experiments. Coimmunoprecipitation is a very powerful technique able to detect the interaction between two target proteins. It may also be used to detect new partners of a bait protein. The bait protein may be purified either via a tag engineered to its sequence or via an antibody specifically targeting it. These protein complexes may then be separated by SDS-PAGE (Sodium Dodecyl sulfate PolyAcrylamide Gel) and identified using mass spectrometry.

Immunoprecipitated LIMK2-1 was also used to test its kinase activity in vitro by γ [³²P] ATP labeling. This well-established assay may use many different substrates, and mutated versions of the bait may be used to assess the role of specific residues. The effects of pharmacological agents may also be evaluated since this technique is both highly sensitive and quantitative. Nonetheless, radioactivity handling requires particular caution. Kinase activity may also be assessed with specific antibodies targeting the phospho group of the modified amino acid. These kinds of antibodies are not commercially available for all the phospho modified residues.

INTRODUCTION:

For many decades, numerous signaling pathways have been elucidated and their involvement in crucial cellular processes such as cell division, differentiation, motility, programmed cell death, immunity and neurobiology, has been shown. Kinases play a significant role in these signaling pathways as they often finely regulate their activation or inactivation and are part of transient versatile complexes that respond to external stimuli¹⁻³. Mutation and dysregulation of kinases often lead to diseases in humans, and they have therefore become one of the most important drug targets over the past forty years⁴.

In this context, it is important to be able to detect kinase interaction with their upstream regulators or downstream substrates and to identify new partners. Affinity purification and immunoprecipitation are very powerful techniques for the isolation of protein complexes⁵. The bait protein or kinase may be tagged with a specific peptide sequence allowing the use of commercial beads covalently coupled with antibodies targeting the peptide. This material permits a high reproducibility in experiments⁶⁻⁸. Endogenous proteins may also be immunoprecipitated using antibodies targeting directly the bait protein. The antibodies may be cross-linked to Protein A or Protein G agarose beads or simply incubated with these beads prior to adding lysate. Lysis buffers must be optimized to allow protein solubilization without losing interaction and to avoid protein degradation. A major drawback of this approach is that the interaction is detected upon cell lysis; therefore, transient or weak interactions, together with those requiring subcellular context may be missed. Other techniques may be used to work directly in the cell such as Proximity Ligation Assay (PLA)⁹, in vivo cross-linking-assisted affinity purification (XAP)¹⁰, Bioluminescence Resonance Energy Transfer (BRET) or Förster Resonance Energy Transfer (FRET)^{11,12}. Furthermore, immunoprecipitation is not appropriate to determine the thermodynamic constants of the binding, for which physical techniques such as Surface Plasmon Resonance, Isothermal Titration Calorimetry or Microscale Thermophoresis are required^{13,14}.

Kinase activity may be assessed using multiple techniques. Herein, we focused on phospho-specific antibodies and in vitro γ [³²P] ATP (Adenosine TriPhosphate) labeling. Phospho-specific antibodies target the phosphate modification of a particular residue within a protein. They may be used in Western Blot or ELISA (Enzyme-Linked ImmunoSorbent Assay) after cell lysis, for immunohistochemistry, and also on intact cells using flow cytometry or immunofluorescence. Their drawbacks may include their lack of specificity, which can be evaluated using a mutated version of the target protein, and their not being commercially available for all proteins. In vitro γ [³²P] ATP labeling is a very robust, well-established and highly sensitive method¹⁵.

Immunoprecipitated or recombinant proteins may be used, and different substrates may be tested. The effects of drugs may also be assessed as this method is quantitative. Its major drawback is that the radioactivity associated with the approach requires handling with caution. Alternative methods are also possible based on the measurement of fluorescent or luminescent peptide substrates and taking advantage of altered fluorescent/luminescent properties upon phosphorylation. Such methods also allow high throughput, which is required, for example, in the screening of molecules that may be potential inhibitors of the target kinase. Indeed, kinases represent one of the largest classes of drug targets pursued by pharmaceutical companies¹⁶.

In this study, we focused on the LIMK2-1 protein (LIMK2-1 stands for Lin11, Isle1, Mec3 Kinase isoform 2-1). The LIMK2 kinase protein was first described in 1995¹⁷. Three isoforms of LIMK2 are produced by alternative splicing: LIMK2a, LIMK2b and LIMK2-1. At present, LIMK2-1 has only been described at the mRNA level in a single study¹⁸. Herein, we characterize this potential new kinase protein at the molecular level using robust biochemical approaches. Firstly, we demonstrate that LIMK2-1 is indeed synthesized. Similar to its two counterparts, LIMK2a and LIMK2b, it interacts with the upstream kinase ROCK (Rho-associated protein kinase). We show LIMK2-1 has a kinase activity on Myelin Basic Protein (MBP), but not on cofilin, the canonical substrate of LIM kinases.

PROTOCOL:

1. Cell preparation for transfection

CAUTION: All the steps of the cell culture must be performed in a dedicated laboratory, and cells are manipulated within a Class 2 microbiological cabinet.

1.1. Seed HEK-293 (Human Embryonic Kidney) cells in Ø 10 cm plates in 10 mL of DMEM (Dulbecco's Modified Eagles Medium) supplemented with 10% fetal calf serum. Culture for 3 to 5 days under 5% CO₂, at 37 °C, until the cells reach ~90% confluence.

1.2. Treat Ø 10 cm plates with Collagen R to increase cell adhesion to the plastic plates.

1.2.1. Add 5 mL of a solution of Collagen R, 200-fold diluted in Phosphate Saline Buffer (PBS) in a Ø 10 cm plate. Overlay the liquid over the whole surface of the plate.

1.2.2. Incubate at room temperature for at least 1 h within the biosafety cabinet.

1.2.3. Remove collagen solution, and discard it. Add 5 mL of PBS, spread it all over the surface of the plate, remove it and discard it. Repeat this wash once.

1.2.4. Add 8 mL of DMEM supplemented with 10% fetal calf serum. Keep the prepared plates within the biosafety cabinet.

1.3. Take HEK-293 plates from step 1.1 within the biosafety cabinet. Remove the medium from

the plates and discard it in a dedicated bleach trash. Add 2 mL of supplemented DMEM, and flush the cells to detach them using the flow of a 1 mL micropipette, taking care to avoid making foam.

1.4. Collect the cells in a 15 mL tube and add 4 mL of supplemented DMEM. Homogenize with a 10 mL pipette, by pipetting up and down 3 times.

1.5. Take 2 mL of this cell solution and add them to collagen-treated plates containing supplemented DMEM from step 1.2.4.

1.6. Grow for 24 hours in the incubator at 5% CO₂ and 37 °C. Cells should be 50-80% confluent at the time of transfection.

2. Transient transfections

2.1. Remove the medium from the plates, discard it in a dedicated bleach trash, and add 10 mL of fresh supplemented DMEM. Put back the plates into the incubator at 37 °C while preparing the transfection mixture.

2.2. In a 15 mL tube, add 450 µL of a 10 mM Tris-HCl pH 7.5/1 mM EDTA (Tris stands for Tris(hydroxymethyl)aminomethane, and EDTA for ethylenedinitrilotetraacetic acid) solution and 50 µL of a 2.5 M CaCl₂ solution. Mix by inversion.

2.3. Add 10 µg of plasmidic DNA (Deoxyribonucleic acid) prepared from a midi preparation on a liquid culture of bacteria transformed with the dedicated plasmid. Mix by inversion.

2.4. Under smooth agitation on a vortex, add 500 µL of BES buffered saline 2x concentrate (composition: BES, 10.7 g/L, NaCl, 16.0 g/L, Na₂HPO₄, 0.27 g/L; BES stands for N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid, N,N-Bis(2-hydroxyethyl)taurine) slowly drop by drop.

2.4. Incubate for at least 15 min (up to 45 min) at room temperature within the biosafety cabinet. Do not vortex, do not mix! Move the tubes very carefully not to disturb the complex formation between DNA and calcium phosphate.

2.5. Take the plates from step 2.1 to the safety cabinet. Add the DNA complexes very carefully, drop by drop, onto the cells all over the surface of the plate.

2.6. Incubate for 24 to 72 hours in the incubator at 37 °C. Usually maximum protein expression is reached within 48 hours.

3. Lysis

NOTE: Work on ice, and with cold buffers to prevent protein degradation.

3.1. Prepare lysis buffer: 50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 5 mM EDTA, 0.1% Triton X-100, 50 mM NaF, 10 mM sodium pyrophosphate, 1 mM Na_3VO_4 , 20 mM p-nitrophenyl phosphate, 20 mM β -glycerophosphate, 10 $\mu\text{g}/\text{mL}$ aprotinin, 0.05 $\mu\text{g}/\text{mL}$ okadaic acid, 1 $\mu\text{g}/\text{mL}$ leupeptin, and 1 mM PMSF (phenylmethylsulfonyl fluoride). Around 4 mL of lysis buffer are required for each transfected plate.

3.2. Remove plates with transfected cells from the incubator. Put them on ice.

NOTE: From this step, it is possible to work on a “normal” bench.

3.3. Remove the media, and discard it in a dedicated bleach trash.

3.4. Wash twice with 3 mL of cold PBS: add 3 mL of PBS on the side of the plate drop by drop to avoid detaching transfected cells, spread all over the surface of the plate, remove PBS and discard it; repeat this step once more. At the end, remove carefully the rest of PBS by tilting the plate to prevent lysis buffer dilution for next step.

3.5. Add 500 μL of cold lysis buffer on the transfected washed cells. Spread it all over the surface of the plate.

3.6. Incubate for 10 min on ice. From time to time (at least twice), spread again the buffer all over the surface of the plate.

3.7. Scrap the cells and collect them in a microcentrifuge tube.

3.8. Centrifuge for 10 min at 10,000 $\times g$ at 4 °C.

3.9. Collect supernatant in a new microcentrifuge tube. This fraction corresponds to the lysate (whole cell extract). Discard the pellet which corresponds to cell membrane debris.

3.10. Collect an aliquot of this fraction to a new microcentrifuge tube (around 50 μL). This fraction corresponds to the “TOTAL fraction” or “Cell Lysate” or “Whole Cell extract” allowing analysis of whether transfected proteins are expressed by Western Blot.

NOTE: At this point, samples can be directly used for Western Blot analyses. Laemmli buffer must to be added to the sample, which is then heated at 95 °C for 5 min, centrifuged at 10,000 $\times g$ for 5 min, and loaded on appropriate SDS-PAGE. Samples may also be stored at -80 °C.

4. Immunoprecipitation

4.1. Gently resuspend agarose beads coupled with the appropriate antibody: HA (Human influenza hemagglutinin), Flag, or GFP (Green Fluorescent Protein) by smooth inversion.

4.2. Cut the end of a 200 μ L tip from a micropipette to allow beads to enter the tip. Pipette the beads up and down several times to saturate the tip to ensure to take the correct volume of beads.

4.3. Take 40 μ L of beads in a microcentrifuge tube.

4.4. Add 500 μ L of TENET (30 mM Tris-HCl pH 7.5, 120 mM NaCl, 5 mM EDTA, 1% Triton X-100) buffer. Mix by inversion. Centrifuge for 2 min at 1,000 $\times g$ at 4 $^{\circ}$ C. Remove carefully supernatant and discard it. Add 500 μ L of TENET. Incubate for at least 1 hour at 4 $^{\circ}$ C on a rotating wheel.

NOTE: This pre-incubation step in TENET allows to reduce non-specific interactions and so to decrease background signal.

4.5. Wash the beads twice with 500 μ L of lysis buffer.

4.5.1. Centrifuge 2 min at 1,000 $\times g$ at 4 $^{\circ}$ C.

4.5.2. Remove carefully supernatant buffer, and discard it.

NOTE: Take care not to aspirate beads during these washing steps.

4.5.3. Add 500 μ L of lysis buffer. Homogenize by inverting the tube.

4.5.4. Repeat steps 4.5.1- 4.5.3.

4.6. Centrifuge for 2 min at 1,000 $\times g$ at 4 $^{\circ}$ C. Carefully remove supernatant buffer, and discard it.

4.7. Incubate beads with the lysate from step 3.9 for 2 to 4 hours at 4 $^{\circ}$ C on a rotating wheel.

4.8. Wash immunoprecipitated beads.

NOTE: At this point, the immunoprecipitated beads may be washed five times with the lysis buffer, and then eluted with Laemmli buffer. The eluate may be used for Western Blot analyses or stored at -80 $^{\circ}$ C. Alternatively, beads may be washed twice with the lysis buffer and then three times with the kinase buffer to perform γ [32 P] ATP labeling.

5. Coimmunoprecipitation analyses

5.1. Wash immunoprecipitated beads from step 4.7 with the lysis buffer.

5.1.1. Centrifuge for 2 min at 1,000 $\times g$ in a refrigerated centrifuge at 4 $^{\circ}$ C.

5.1.2. Carefully remove the supernatant, and discard it.

5.1.3. Add 500 μ L of lysis buffer. Homogenize by inverting the tube.

5.1.4. Repeat steps 5.1.1-5.1.3 four times.

5.2. Elution

5.2.1. Centrifuge for 2 min at 1,000 x *g* in a refrigerated centrifuge at 4 °C.

5.2.2. Carefully remove the supernatant, and discard it. Remove the last drops of supernatant with a Hamilton syringe in order to avoid aspiration of the beads, and discard the supernatant.

5.2.3. Add 40 μ L of 4x Laemmli buffer (200 mM Tris/HCl pH 6.8, 4% SDS, 40% glycerol, 0.5 M β -mercaptoethanol, 0.02% bromophenol blue). Homogenize by gently tapping the tube.

5.2.4. Incubate for 5 min at room temperature.

5.2.5. Centrifuge for 5 min at 10,000 x *g* at room temperature.

5.2.6. With a Hamilton syringe, remove the supernatant and collect it in a new microcentrifuge tube. This fraction corresponds to the "Eluate", which may be stored at -80 °C, or directly analyzed by Western Blot.

6. Kinase assay

6.1. Prepare the kinase buffer: 50 mM HEPES-NaOH pH 7.5 (HEPES stands for 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 150 mM NaCl, 5 mM MgCl₂, 5 mM MnCl₂, 50 mM NaF, 1 mM Na₃VO₄, 20 mM β -glycerophosphate, 1 μ g/mL leupeptin, and 1 mM PMSF. Around 2 mL of the kinase buffer is required for each immunoprecipitation condition.

6.2. Wash immunoprecipitated beads from step 4.7 twice with 500 μ L of lysis buffer.

6.2.1. Centrifuge for 2 min at 1,000 x *g* in a refrigerated centrifuge at 4 °C.

6.2.2. Carefully remove supernatant, and discard it. Add 500 μ L of lysis buffer. Homogenize by inversion.

6.2.3. Repeat steps 6.2.1 and 6.2.2.

6.3. Wash immunoprecipitated beads three times with 500 μ L of kinase buffer.

6.3.1 Centrifuge for 2 min at 1,000 x *g* in a refrigerated centrifuge at 4 °C.

307
308 6.3.2. Carefully remove supernatant, and discard it. Add 500 μL of kinase buffer. Homogenize
309 by inversion.
310
311 6.3.3. Repeat steps 6.3.1 and 6.3.2 twice.
312
313 6.4. Centrifuge for 2 min at 1,000 $\times g$ in a refrigerated centrifuge at 4 $^{\circ}\text{C}$.
314
315 6.5. Carefully remove supernatant, and discard it. Remove the last drops of supernatant with a
316 Hamilton syringe in order to avoid aspiration of the beads, and discard the supernatant.
317
318 6.6. Add 40 μL of kinase buffer to the immunoprecipitated beads. Resuspend the beads by
319 gently tapping the tube.
320
321 6.7. Prepare the mix for the $\gamma[^{32}\text{P}]$ ATP labeling (final volume is 22.5 μL , complete with kinase
322 buffer) in a safe lock-tube.
323
324 6.7.1. Add the required volume of kinase buffer to reach a final volume of 22.5 μL .
325
326 6.7.2. Cut the end of a 20 μL tip of a micropipette. Resuspend the immunoprecipitated beads
327 from step 6.6 by pipetting up and down several times. Collect 10 μL of these beads into the
328 safe-lock tube.
329
330 6.7.3. Add ATP from a 10 mM stock solution to reach 50 μM of finale concentration. According
331 to the number of sample treated, a dilution of the stock solution of ATP in the kinase buffer is
332 suggested to allow to pipette 1 to 2 μL , to be sure the volume is correct.
333
334 6.7.4. Add 2.5 μg of substrate (cofilin or Myelin Basic Protein, MBP in the present study case).
335
336 6.8. Add 5 μCi of $\gamma[^{32}\text{P}]$ ATP (3,000 Ci/mmol) to initiate the reaction. Mix by pipetting up and
337 down slowly.
338
339 CAUTION: From this point, work must be done in a safety place dedicated for radioactivity
340 manipulations with cautious precaution, dedicated protections and appropriate controls
341 (radioactive shields, Geiger counter, specific waste collect, personal breast and finger badges to
342 detect radioactive exposure, filter tips).
343
344 6.9. Incubate for 20 min at 30 $^{\circ}\text{C}$.
345
346 6.10. Stop the reaction with 6 μL of 5x Laemmli buffer.
347
348 6.11. Heat at 95 $^{\circ}\text{C}$ for 5 min.
349

350 6.12. Centrifuge at 10,000 x *g* for 5 min at room temperature.

351
352 6.13. Load on a SDS-PAGE. Proceed to migration.

353
354 NOTE: Take care that the front line of free γ [³²P] ATP does not exit the gel to avoid
355 contamination of the migration tank.

356
357 6.14. Stain the gel at room temperature.

358
359 6.14.1. Remove the gel from the glass plates.

360
361 6.14.2. Proceed with three baths in water at room temperature.

362
363 6.14.3. Stain the gel overnight with Coomassie Blue at room temperature.

364
365 6.14.4. Destain the gel with several wash baths with water at room temperature.

366
367 6.15. Wrap the gel with plastic wrap.

368
369 6.16. Expose for one night or more on a phosphorimager screen.

370
371 6.17. Read the screen on a phosphorimager to detect labeled bands.

372 373 **REPRESENTATIVE RESULTS:**

374 **LIMK2-1 protein is synthesized**

375 LIMK2-1 is mentioned in databanks, but thus far only one paper has shown the existence of its
376 mRNA¹⁸. Compared to its two homologs, LIMK2a and LIMK2b, LIMK2-1 has an extra C-terminal
377 domain identified as a Protein Phosphatase 1 Inhibitory domain (PP1i). We designed an
378 antibody that targets a peptide of this domain, amino acids 671-684 (**Figure 1A**).
379 BLAST research against human protein databases showed that only one protein, PHI-1
380 (Phosphatase holoenzyme inhibitor 1), has a strong sequence similarity with this 12 amino acid
381 sequence. However, PHI-1 migrates at 23 kDa on SDS-PAGE gels, far away from LIMK2-1, which
382 is expected to migrate around 75 kDa (i.e., the two should not interfere). We validated this
383 antibody firstly for HEK-293 cells transfected either with LIMK2-1, LIMK2a, or LIMK2b and
384 showed that the anti-PP1i antibody was able to recognize transfected LIMK2-1 (pCMV-LIMK2-1)
385 and HA-tagged LIMK2-1, but did not cross-react with transfected HA-tagged LIMK2a or LIMK2b
386 (**Figure 1B**). We observed a band of endogenous LIMK2-1 in HEK cells transfected with HA-
387 tagged versions of the LIMK2 isoforms (indicated by an arrow in the anti-PP1i blot; **Figure 1B**).
388 Secondly, we checked whether the signal induced by the anti-PP1i antibody was specific to
389 LIMK2-1 using siRNA targeting the three spliced variants of LIMK2 (**Figure 1C**). In the presence
390 of LIMK2 siRNA, a reproducible and significant decrease in the band of interest was observed
391 (indicated by an arrow in **Figure 1C**) compared to control conditions, suggesting that the
392 antibody is specific to LIMK2-1. Following this, we used the anti-PP1i antibody to detect LIMK2-
393 1 in different cell line extracts: HEK-293 (Human Embryonic Kidney cells), HeLa (Human

Epithelial Cervix cells), and C6 (Rat Brain Glial cells). These cells are disrupted in the lysis buffer containing 1% Triton X-100. Using in silico analysis, LIMK2-1 was shown to be *Hominidae* primate-specific¹⁹. Western Blot analysis using the anti-PP1i antibody showed that LIMK2-1 appeared to be expressed in HEK-293 and HeLa but not in C6 cell lines as expected from in silico studies (**Figure 1D**). These experiments were repeated with various human tissues, showing that levels of LIMK2-1 protein varied depending on the tissue: the highest levels were found in liver, lesser levels in pancreas, and the lowest in the testis and lung. LIMK2-1 was not detectable in brain tissue (**Figure 1E**). We observed lower molecular weight bands in all tissue samples except liver, suggesting the degradation of the full protein probably due to the lysis conditions of these commercial samples (this lysis buffer contains a cocktail of inhibitors not specified on the data sheet, which may be less efficient than the numerous protease and phosphatase inhibitors we are using in our home-made buffer). These data show that human LIMK2-1 protein is synthesized and expressed differently in the tested tissues.

LIMK2-1 interacts with its upstream kinase ROCK

LIMK2-1 homologs, LIMK2a and LIMK2b, have been described as regulated by the upstream kinase ROCK. We assessed the interaction of LIMK2-1 with ROCK using coimmunoprecipitation experiments. HEK cells were co-transfected with vectors encoding cMyc-tagged ROCK1 and either one of the HA-tagged version of LIMK2 isoforms, or the unrelated HA-tagged protein Larp6. Larp6 serves as a negative control, permitting the detection of non-specific interactions. Cells were lysed and anti-HA immunoprecipitation was performed. Lysates (whole cell extracts) and immunoprecipitates were analyzed by Western Blot, using anti-HA and anti-cMyc antibodies. As depicted in **Figure 2** (left panels; Lysates), each of the different proteins encoded by the transfected vectors are well expressed. The three isoforms of LIMK2, as well as Larp6, are efficiently immunoprecipitated (**Figure 2**, bottom right panel; Eluates). In the eluates, ROCK is detected and thus coimmunoprecipitated with the three isoforms of LIMK2, but not with Larp6 (**Figure 2**, top right panel; Eluates). This demonstrates that ROCK interacts with the three isoforms of LIMK2, especially with the newly characterized isoform LIMK2-1. This interaction is specific since the negative control (Larp6) does not interact with ROCK.

Herein, we present data for the immunoprecipitation performed with anti-HA antibodies; however, the interaction may be tested in the opposite direction by immunoprecipitating ROCK with beads conjugated with cMyc antibodies and analyzing eluates with HA antibodies to detect LIMK coimmunoprecipitation.

Kinase activity

Phospho-cofilin in intact cells

The homologs of LIMK2-1, LIMK2a and LIMK2b, have been shown to phosphorylate cofilin, an actin depolymerisation factor, on its Serine3. Using an antibody specifically targeting the phospho-Serine3 of cofilin, we studied LIMK2 kinase activity by measuring the level of endogenous phospho-cofilin in HEK cells overexpressing one of the LIMK2 isoforms. HEK cells were transfected with vectors encoding either one of the HA-tagged LIMK2 isoforms, or the corresponding empty vector as a negative control. Cells were lysed, and the different lysates were analyzed by Western Blotting using the anti-phospho-Serine3 cofilin antibody. The

overexpression of LIMK2a and LIMK2b induced a significant and reproducible increase in phospho-cofilin levels relative to control conditions, whereas the presence of LIMK2-1 had no detectable effect (**Figure 3**, left panel).

We repeated the same experiment with a C-terminal YFP-tagged (Yellow Fluorescent Protein) version of the three LIMK2 isoforms and an untagged version of LIMK2-1 to rule out possible interference by the N-terminal HA tag. The results were identical to those obtained using HA-tagged versions of the three isoforms (**Figure 3**, right panel showing the YFP tagged version). Transfection efficiency was assessed for the YFP-tagged version of LIMK isoforms using flow cytometry to rule out that this result may have been due to difference of protein expression. The three isoforms showed similar transfection efficiency: 54% for LIMK2-1, 49% for LIMK2b and 43% for LIMK2a.

In vitro kinase tests

We then studied the kinase activity of the LIMK2 isoforms by in vitro labeling with γ [³²P] ATP. **Figure 4A** shows the general scheme of this in vitro labeling. HEK cells were transfected with either one of the HA-tagged versions of the LIMK2 isoforms or the unrelated protein, Larp6, which was used as a negative control. The kinase activity of the anti-HA immunoprecipitates was measured using recombinant GST-cofilin as a substrate in the presence of γ [³²P] ATP. HA-immunoprecipitated Larp6 showed no kinase activity on cofilin. HA-immunoprecipitated LIMK2a and LIMK2b phosphorylated cofilin, whereas LIMK2-1 did not (**Figure 4B**). We obtained similar results using YFP-tagged versions of the three isoforms immunoprecipitated with GFP-trap beads in the presence of recombinant cofilin and γ [³²P] ATP (**Figure 4D**).

We then tested whether LIMK2-1 had no kinase activity or if its activity on cofilin was impaired. We repeated the in vitro labeling experiment using Myelin Basic Protein (MBP), an efficient substrate for numerous protein kinases, instead of cofilin. There was a high background signal in the control condition when the assay was performed in the presence of HA-tagged versions: the negative control, HA-immunoprecipitated Larp6, produced a strong signal of phosphorylated MBP, although it is not a kinase (**Figure 4C**). We overcame this problem using the YFP-tagged version of these proteins. Under these conditions, the background in the control (YFP alone) was low, allowing more specific studies to be conducted. GFP-trapped YFP-LIMK2a, LIMK2b, and LIMK2-1 showed kinase activity towards MBP, although the activity of LIMK2-1 was lower (**Figure 4D**). However, LIMK2-1 was also less efficiently immunoprecipitated under these conditions (see Coomassie Brilliant Blue (CBB) staining and Western Blotting). Thus, the three isoforms showed comparable activity on MBP when phospho-MBP was normalized to immunoprecipitated LIMK2 levels by CBB staining (**Figure 4D**, lower panel). Immunoprecipitates were also analyzed by Western Blot using anti-ROCK antibodies to check if the activity on MBP could be due to the presence of ROCK, which would have been coimmunoprecipitated with LIMK2s. We could not detect any ROCK signal in LIMK2 immunoprecipitates. So MBP phosphorylation is not due to ROCK but to LIMK2s per se.

Overall, these data show that LIMK2a and LIMK2b have similar activities on cofilin and MBP. Although LIMK2-1 shows kinase activity towards MBP comparable to that of the other two

isoforms, cofilin is not a good substrate for it.

FIGURE AND TABLE LEGENDS:

Figure 1. Evidence for the existence of the LIMK2-1 protein. (A) Schematic diagram of the three isoforms of human LIMK2. LIMK2 isoforms are described in Entrez Gene: LIMK2-1 (NP_001026971.1), LIMK2a (NP_005560.1), LIMK2b (NP_057952.1). The various domains of LIMK2 are shown: LIM (Lin11, Isl1, Mec3), LIM' (shorter LIM domain), PDZ (PSD95, Dlg1, Zo-1), S/P (Serine Proline rich), Kinase' (shorter kinase domain), and PP1i (Protein Phosphatase 1 inhibitory). The sequence chosen for anti-PP1i antibody design is shown in red. (B and C) Validation of the anti-LIMK2-1 antibody. (B) HEK-293 cells were transfected with untagged LIMK2-1 (pCMV-LIMK2-1) or one of the HA-tagged isoforms of LIMK2. Lysates were analyzed by Western Blotting using the indicated antibodies. (C) HEK-293 cells were transfected either with LIMK2 siRNA or control siRNA. Lysates were analyzed by Western Blot. LIMK2-1 is expressed in various human cell lines (D) and tissues (E). HEK-293, HeLa and C6 cells were disrupted in 1% Triton-X100 lysis buffer. Tissue extracts were purchased and samples thereof were analyzed by Western Blotting. This figure was modified from Vallee et al., The Biochemical Journal, 2018, <http://www.biochemj.org/content/475/23/3745.long>²⁰.

Figure 2: The three isoforms of LIMK2 interact with ROCK1. HEK-293 cells were co-transfected with cMyc-tagged ROCK1 and either one of the three HA-tagged LIMK2 isoforms (2-1, 2a, 2b) or the unrelated protein, Larp6. Lysates and anti-HA immunoprecipitates were subjected to Western Blotting.

Figure 3: LIMK2-1 has no kinase activity towards cofilin in intact cells. HEK-293 cells were transfected with either one of the three HA-tagged LIMK2 isoforms (1, 2a, 2b) or the empty parental vector, pcDNA3 (left panel), or with either one of the three YFP-tagged LIMK2 isoforms or YFP alone (right panel). Lysates were subjected to Western Blotting. Quantification of the ratio of phospho-cofilin versus cofilin is shown in the graph on the right. The phospho-cofilin versus cofilin ratio of mock transfected cells was normalized to 100. Each value represents the mean \pm SE of three independent experiments. This figure was modified from Vallee et al., The Biochemical Journal 2018, <http://www.biochemj.org/content/475/23/3745.long>²⁰.

Figure 4: LIMK2-1 has no in vitro kinase activity towards cofilin, although it phosphorylates MBP. (A) General scheme of γ [³²P] ATP in vitro labeling. (B) *LIMK2-1 does not phosphorylate cofilin* in vitro. HEK-293 cells were transfected with either one of the three HA-tagged LIMK2 isoforms (2-1, 2a, 2b) or an unrelated HA-tagged protein, Larp6, as a negative control. Anti-HA immunoprecipitated proteins and GST-cofilin were used in the kinase assay. The anti-HA immunoprecipitates were also subjected to anti-HA immunoblotting and Coomassie blue staining. (C) *HA-tagged immunoprecipitation has a strong background signal when MBP is used as a substrate.* HEK-293 cells were transfected with either one of the three HA-tagged LIMK2 isoforms (2-1, 2a, 2b) or an unrelated HA-tagged protein, Larp6, as a negative control. Anti-HA immunoprecipitated proteins and MBP were used in the kinase assay. The anti-HA immunoprecipitates were also subjected to anti-HA immunoblotting and Coomassie blue staining. (D) *The three LIMK2 isoforms have kinase activity towards Myelin Basic Protein (MBP).*

HEK-293 cells were transfected with either one of the three YFP-tagged LIMK2 isoforms (2-1, 2a, 2b) or YFP alone. Anti-GFP immunoprecipitated LIMK2 isoforms and cofilin or MBP were used in the kinase assay. The anti-GFP immunoprecipitates were also subjected to anti-GFP immunoblotting and Coomassie blue staining. Quantification of phospho-cofilin and phospho-MBP is shown in the bottom graph. Phospho-cofilin levels obtained with anti-GFP immunoprecipitated LIMK2a were normalized to 100. Each value represents the mean \pm SE of three independent experiments. This figure was modified from Vallee et al., The Biochemical Journal, 2018, <http://www.biochemj.org/content/475/23/3745.long>²⁰.

DISCUSSION:

Herein, we have used robust biochemical tools to characterize at the molecular level a new protein, LIMK2-1, believed to be a kinase based on its sequence and on its homologs, LIMK2a and LIMK2b²⁰.

Firstly, we demonstrated the existence of LIMK2-1 at the protein level using Western Blot analysis with a specific antibody. Following this, we evaluated its interaction with the upstream kinase ROCK1, which is known to regulate LIMK2a and LIMK2b, the homologs of LIMK2-1. Finally, we assessed the potential kinase activity of LIMK2-1 through in vitro γ [³²P] ATP labeling and in cellulo by Western Blot using a specific phospho-antibody.

Lysis buffer composition

When studying proteins in order to analyze them by Western Blot, particular care is required with respect to lysis buffer composition. Several parameters have to be considered: (i) detergent type and concentration²¹, and (ii) protease inhibitors.

The lysis buffer composition must be adapted to the target protein to facilitate its near complete solubilization in order to extract it as much as possible and to allow its detection by Western Blot. For soluble proteins, mild conditions (e.g., a mild detergent at low concentration) are often sufficient to achieve this. For membrane proteins, stronger conditions are typically often required. Different categories of detergents exist: (i) ionic, such as sodium dodecyl sulfate (SDS), cetyltrimethylammonium bromide (CTAB), (ii) non-ionic such as Polyethylene glycol hexadecyl ether (BRIJ), Triton, octylglucoside (OG), dodecylmaltoside (DDM), and (iii) zwitterionic such as 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) or zwittergents. Strong detergents may disrupt interactions and complexes may be lost. Moreover, for immunoprecipitation experiments, antibodies may be sensitive to severe conditions. Similarly, enzyme activity may be disturbed by the presence of detergents that may unfold or denature the studied protein. Both the type and quantity of the detergent used may affect the properties and the activity of a protein. For some proteins, a very restricted range of concentration of detergent is tolerated to preserve the activity of the protein. Below this range the protein remains insoluble whereas above this range of concentration, the protein is no longer active.

Protease inhibitors must be added to the lysis buffer to prevent degradation of the target protein by endogenous proteases. Protease inhibitor cocktails are commercially available. They

can be used as a starting point of a study. If troubles are encountered, one may consider the use of a mixture of inhibitors extemporarily prepared from stock solutions stored at -20 °C. These inhibitors must target serine and cysteine proteases. PMSF (Phenylmethylsulfonyl fluoride) is commonly used, however it is very unstable in aqueous solution and must be added just before the extraction. Metalloproteases should also be inhibited: metal chelating reagents, such as EDTA (Ethylenedinitrilotetraacetic acid) or EGTA (Ethylene glycol-bis(2-aminoethylether)-tetraacetic acid), which bind to Mg^{2+} , are used in this purpose. To keep protein in their phosphorylated and thus activated form, it is also recommended to add phosphatase inhibitors to the lysis buffer. These inhibitors must target alkaline, acid, serine, threonine, and tyrosine phosphatases. Working at low temperature (4 °C) is also recommended in order to slow down the rate of proteolysis.

Target proteins

Herein, we focused on epitope-tagged proteins. Tags (Flag, HA, cMyc, GFP, etc.) are very useful in order to detect and purify proteins, as antibodies and antibody coupled beads are commercially available and are readily reproducible materials. However, the size and the position of the tag has to be considered as this may affect the activity, localization or function of the target protein⁶⁻⁸. It is also possible to work with endogenous proteins. In this case, antibodies targeting this particular protein must be used. They may be coupled to beads (Protein A or Protein G) covalently (cross-link) or be incubated with the lysate and then with the beads. When working with tagged proteins, whose gene is expressed on a plasmid, it is easy to switch to a mutated version of this protein by mutagenesis of the gene. It is then possible to work on different mutants to assess biological functions.

Immunoprecipitation

Immunoprecipitation is a very powerful technique to isolate partners of the target protein⁵. The composition of the lysis buffer (especially detergent) has to be carefully established to preserve interactions (see above). It is possible to detect the interaction between two identified proteins. It may be endogenous proteins or overexpressed proteins. When proteins are expressed at low abundance, it may be necessary to overexpress them in order to have stronger signals. Extensive washes of immunoprecipitated beads are required to remove non-specifically interacting proteins or contaminants. Prior to determining immunoprecipitation efficiency or co-immunoprecipitated partner presence, it is important to check that the different partners are well expressed and present in the lysate by analyzing the whole cell lysate or the input fraction by Western Blot. Furthermore, using immunoprecipitation experiments, it is also possible to identify new partners of a target protein and to isolate new complexes. These new partners may be identified by mass spectrometry.

Such partners may play an important role as activators of the target protein allowing its full activity for further biological tests. On the other hand, copurified unwanted proteins may be used as an argument that there is not a direct interaction between two identified partners, but instead that the detected interaction by co-immunoprecipitation is due to another unknown partner. In this specific case, to be sure of a direct interaction, another experimental device is needed, such as working on mammalian proteins purified from bacteria.

Kinase activity

Kinase activity may be assessed by different techniques. Herein, we focused on in vitro analysis by $\gamma[^{32}\text{P}]$ ATP labeling and on whole cell extract analysis by Western Blot using a specific phospho-antibody. $\gamma[^{32}\text{P}]$ ATP labeling is a very sensitive and quantitative technique allowing the detection of weak kinase activity¹⁵. Radioactivity incorporation from ATP to the target substrate allows a direct measure of enzyme activity to be made. It is possible to work with different substrates to assess the kinase activity of the studied protein on different targets. It is also possible to identify amino acids crucial for kinase activity by mutating them when the protein is overexpressed. Kinase activity requires a divalent cation such as Mg^{2+} , which has to be present in the kinase buffer.

The major drawback of this approach is the handling of radioactivity, which requires dedicated facilities for experiments and for the collection of wastes. Alternative methods exist, such as fluorescent or luminescent kits that detect byproducts of the reaction, such as ADP (adenosine diphosphate)¹⁶. Protein phosphorylation may also be studied by mass spectrometry, however, a larger amount of materials is required for these analyses. In our case, we tried to assess LIMK2 kinase activity using capillary electrophoresis to increase our efficiency but this was unfortunately unsuccessful.

Phosphospecific antibodies are a further tool to study the phosphorylation of a protein. Broad general anti-phospho Serine and Tyrosine antibodies exist, able to recognize phospho-Ser or phospho-Tyr of any proteins. In recent years, antibodies targeting a specific phospho-site of a target protein have been widely developed and usually they recognize both the phospho group and the surrounding amino acids. Special care is needed when starting to work with such antibodies, as their specificity must be checked for example with a negative control, such as the target protein mutated on the phospho site. When probing a blot with an anti-phospho antibody, the blocking solution must not be milk, as this contains phosphoproteins that may interact with the antibody. Bovine Serum Albumin (BSA) is recommended, and phosphatase inhibitors may be added in the blocking solution to prevent phosphate release. Samples should not be frozen and thawed, but rather prepared as aliquots which are kept at -80°C . Indeed, phospho modifications are labile.

ACKNOWLEDGMENTS:

This work was supported by La Ligue contre le Cancer, l'Association Neurofibromatoses et Recklinghausen, and la Région Centre Val de Loire. Many thanks to Aurélie Cosson and Déborah Casas for flow cytometry data, and to Keyron Hickman-Lewis for thorough proofreading of the manuscript.

DISCLOSURES:

The authors have nothing to disclose.

REFERENCES:

- 1 Manning, G., Plowman, G. D., Hunter, T., Sudarsanam, S. Evolution of protein kinase

signaling from yeast to man. *Trends in Biochemical Sciences*. **27**, 514-520 (2002).

- 2 Manning, G., Whyte, D. B., Martinez, R., Hunter, T., Sudarsanam, S. The protein kinase complement of the human genome. *Science (New York, N.Y.)*. **298**, 1912-1934, doi:10.1126/science.1075762 (2002).
- 3 Ochoa, D., Bradley, D., Beltrao, P. Evolution, dynamics and dysregulation of kinase signalling. *Current Opinion in Structural Biology*. **48**, 133-140, doi:10.1016/j.sbi.2017.12.008 (2018).
- 4 Bhullar, K. S. et al. Kinase-targeted cancer therapies: progress, challenges and future directions. *Molecular Cancer*. **17**, 48, doi:10.1186/s12943-018-0804-2 (2018).
- 5 Kaboord, B., Perr, M. Isolation of proteins and protein complexes by immunoprecipitation. *Methods in Molecular Biology (Clifton, N.J.)*. **424**, 349-364, doi:10.1007/978-1-60327-064-9_27 (2008).
- 6 Arnau, J., Lauritzen, C., Petersen, G. E., Pedersen, J. Current strategies for the use of affinity tags and tag removal for the purification of recombinant proteins. *Protein Expression and Purification*. **48**, 1-13, doi:10.1016/j.pep.2005.12.002 (2006).
- 7 Wood, D. W. New trends and affinity tag designs for recombinant protein purification. *Current Opinion in Structural Biology*. **26**, 54-61, doi:10.1016/j.sbi.2014.04.006 (2014).
- 8 Young, C. L., Britton, Z. T., Robinson, A. S. Recombinant protein expression and purification: a comprehensive review of affinity tags and microbial applications. *Biotechnology Journal*. **7**, 620-634, doi:10.1002/biot.201100155 (2012).
- 9 Greenwood, C. et al. Proximity assays for sensitive quantification of proteins. *Biomolecular Detection and Quantification*. **4**, 10-16, doi:10.1016/j.bdq.2015.04.002 (2015).
- 10 Wang, X., Huang, L. Dissecting Dynamic and Heterogeneous Proteasome Complexes Using In vivo Cross-Linking-Assisted Affinity Purification and Mass Spectrometry. *Methods in Molecular Biology (Clifton, N.J.)*. **1844**, 401-410, doi:10.1007/978-1-4939-8706-1_25 (2018).
- 11 Raykova, D. et al. Let There Be Light! *Proteomes*. **4**, doi:10.3390/proteomes4040036 (2016).
- 12 Weibrecht, I. et al. Proximity ligation assays: a recent addition to the proteomics toolbox. *Expert Review of Proteomics*. **7**, 401-409, doi:10.1586/epr.10.10 (2010).
- 13 Podobnik, M. et al. How to Study Protein-protein Interactions. *Acta Chimica Slovenica*. **63**, 424-439 (2016).
- 14 Rao, V. S., Srinivas, K., Sujini, G. N., Kumar, G. N. Protein-protein interaction detection: methods and analysis. *International Journal of Proteomics*. **2014**, 147648, doi:10.1155/2014/147648 (2014).
- 15 Peck, S. C. Analysis of protein phosphorylation: methods and strategies for studying kinases and substrates. *The Plant Journal: For Cell and Molecular Biology*. **45**, 512-522, doi:10.1111/j.1365-3113X.2005.02613.x (2006).
- 16 Jia, Y., Quinn, C. M., Kwak, S., Talanian, R. V. Current in vitro kinase assay technologies: the quest for a universal format. *Current Drug Discovery Technologies*. **5**, 59-69 (2008).
- 17 Okano, I. et al. Identification and characterization of a novel family of serine/threonine kinases containing two N-terminal LIM motifs. *The Journal of Biological Chemistry*. **270**, 31321-31330 (1995).

702 18 Croft, D. R. et al. p53-mediated transcriptional regulation and activation of the actin
703 cytoskeleton. *Cell Research*. **21**, 666-682 (2011).


704 19 Tastet, J. et al. LIMK2-1 is a Hominidae-Specific Isoform of LIMK2 Expressed in Central
705 Nervous System and Associated with Intellectual Disability. *Neuroscience*. **399**, 199-210,
706 doi:10.1016/j.neuroscience.2018.12.017 (2019).

707 20 Vallee, B. et al. LIMK2-1, a new isoform of human LIMK2, regulates actin cytoskeleton
708 remodeling via a different signaling pathway than that of its two homologs, LIMK2a and
709 LIMK2b. *The Biochemical Journal*. **475**, 3745-3761, doi:10.1042/bcj20170961 (2018).


710 21 Lee, Y. C. et al. Impact of Detergents on Membrane Protein Complex Isolation. *Journal of*
711 *Proteome Research*. **17**, 348-358, doi:10.1021/acs.jproteome.7b00599 (2018).
712

Figure 1 - JOVE Vallee revised


A




B



C



D



E




Figure 2 - JOVE Vallee




Figure 3 - JOVE-Vallee





Figure 4 - JOVE-Vallee



Name of Material/ Equipment	Company	Catalog Number	Comments/Description
Antibody anti-actin	Sigma-Aldrich	A1978	for Western Blot
Antibody anti-c-Myc	Invitrogen	MA1-21316	for Western Blot
Antibody anti-cofilin	Cell signaling Technology	3312/5175	for Western Blot
Antibody anti-GFP	Santa Cruz	sc-9996	for Western Blot
Antibody anti-HA	Roche Applied Science	11687423001	for Western Blot
Antibody anti-phospho-cofilin	Cell signaling Technology	3313	for Western Blot
Antibody Anti-PP1i	Eurogentec	designed for this study	for Western Blot
Aprotinin	Euromedex	A-162B	for lysis buffer
ATP	Invitrogen	PV3227	for γ [32 P] labeling
γ [32 P] ATP	Perkin Elmer	NEG502A	for γ [32 P] labeling
BES buffered saline	Sigma-Aldrich	14280	for transfection
β -glycerophosphate	Sigma-Aldrich	G9422	for lysis and kinase buffer
β -mercaptoethanol	Sigma-Aldrich	M3148	for Laemmli
BSA	Sigma-Aldrich	A3059	for blocking buffer
Bromophenol Blue	Sigma-Aldrich	B0126	for Laemmli
CaCl ₂	Sigma-Aldrich	C3881	for transfection
Centrifuge	Sigma	111-541	
Collagen R	Pan Biotech	P06-20166	for transfection
Control siRNA	Ambion	AM4611	for PP1i antibody specificity
Coomassie PageBlue Protein Staining Solution	Thermo-Fisher	24620	for gel staining
EDTA	Sigma-Aldrich	3690	for lysis buffer
Electrophoresis Unit	Biorad	Mini-Protean	for Western Blot
EZview Red anti-HA affinity gel	Sigma-Aldrich	E6779	for immunoprecipitation
GeneSys software	Ozyme		for Western Blot acquisition
GeneTolls software	Ozyme		for Western Blot quantification
GFP-trap beads	Chromtek		for immunoprecipitation
Glycine	Euromedex	26-128-6405	for transfer buffer
GST-cofilin	Upstate Cell signaling	12-556	for γ [32 P] labeling
Hamilton syringe 100 μ L	Hamilton	710	to remove carefully supernatant from beads without aspirating them
HEPES	Sigma-Aldrich	H3375	for kinase buffer
ImageQuant TL software	GE Healthcare		for radioactivity acquisition and quantification
LIMK2 siRNA	Ambion	s8191	for PP1i antibody specificity
Leupeptin	Sigma-Aldrich	SP-04-2217	for lysis and kinase buffer
MBP	Upstate Cell signaling	13-173	for γ [32 P] labeling
MgCl ₂	Sigma-Aldrich	M8266	for kinase buffer
MnCl ₂	Sigma-Aldrich	244589	for kinase buffer
NaCl	Euromedex	1112	for lysis and kinase buffer
NaF	Sigma-Aldrich	S-1504	for lysis and kinase buffer
Okaidic acid	Euromedex	0-2220	for lysis buffer
PMSF	Sigma-Aldrich	78830	for lysis and kinase buffer
p-nitrophenylphosphate	Euromedex	1026	for lysis buffer
PVDF membrane Immobilon-P	Merck-Millipore	IPVH00010 pore size 0,45 μ m	for Western Blot
Rotating wheel	Labinco		for bead incubation
Safe lock eppendorf	Eppendorf	0030120.086	for kinase assay
SDS	Sigma-Aldrich	5030	for Laemmli and migration buffer
Sodium orthovanadate	LC Laboratories	S8507	for lysis and kinase buffer
Sodium pyrophosphate	Fluka	71501	for lysis buffer
Super Signal West Dura	Protein Biology	34075	for Western Blot
Syngene Pxi	Ozyme		for Western Blot
Tissue extracts	Biochain	P1234035 Brain P12345152 Lung P1234149 Liver P1234188 Pancreas P1234260 Testis	for Western Blot analysis
Transfer Unit	Biorad	Mini-Trans-Blot	for Western Blot
Tris	Euromedex	26-128-3094 B	for lysis buffer
Tween-20	Sigma-Aldrich	P7949	for blocking buffer
Typhoon FLA9500	GE Healthcare		to read autoradiography
Typhoon Trio	Amersham Bioscience		to read autoradiography
Whatman paper	GE Healthcare	3030-672	for Western Blot

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:	Characterization at the molecular level by robust biochemical approaches of a new kinase protein
Author(s):	Béatrice Vallée, Michel Doudeau, Fabienne Godin, and Hélène Bénédicti

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:

☒ Standard Access

☐ Open Access

Item 2: Please select one of the following items:

☒ The Author is **NOT** a United States government employee.

☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.

☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to


the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication of the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

CORRESPONDING AUTHOR

Name:	Beatrice Vallee		
Department:	Centre de Biophysique Moléculaire, UPR4301		
Institution:	CNRS		
Title:	Ph.D.		
Signature:		Date:	11/02/2019

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140

Editorial comments:

1. There are some scattered typos throughout. Please read through the manuscript once more for a final polish.

The manuscript has been carefully read.

2. There are 4 pages of protocol text highlighted. Please note that we can only have 2.75 pages of protocol text highlighted to ensure that videography can occur in a single day.

Protocol text highlighted has been reduced to 2.75 pages

3. Please provide a complete reference for Reference 18.

Reference 18 has been corrected.

4. Please ensure that all acronyms are defined. Please define BES and what is its composition?

Acronyms are defined. BES has been defined, and its composition specified

.



Portland Press – Production <production@portlandpress.com>

■ VALLEE MEHEUST Beatrice

11

RE: copyright permission

 Assurer un suivi. Commencer avant jeudi 7 mars 2019. Échéance le jeudi 7 mars 2019.

Dear Dr Vallée

Thank you for your email. Please regard this message as permission to reuse figures 1-8 from 'LIMK2-1, a new isoform of human LIMK2, regulates actin cytoskeleton remodeling via a different signaling pathway than that of its two homologs, LIMK2a and LIMK2b' in *Biochemical Journal* at no charge, subject to the following conditions:

1. Your reproduced figures must cite the article and author, both in the reference list and in the figure legends.
2. Please include a hyperlink to the article on the journal site when referencing/citing the figures.
1. If you modify an original figure in any way, please ensure that it is labelled as a modified version of the original.
2. If modified, this/these version/s should not imply approval from the original authors, unless such approval is separately sought.

If you also require a formal licence, please visit copyright.com and make your request following the steps on this site.

Please note that whilst we do not charge for re-using figures in the manner that you are requesting, you may be charged an admin fee of \$3.50 USD by the Copyright Clearance Center if you seek permission on copyright.com.

With best wishes

Stuart Weir